- Home
- REGN
as 02-21-2025 4:00pm EST
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 110.0B | IPO Year: | 1991 |
| Target Price: | $996.00 | AVG Volume (30 days): | 905.6K |
| Analyst Decision: | Buy | Number of Analysts: | 26 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | 38.34 | EPS Growth: | 10.27 |
| 52 Week Low/High: | $642.00 - $1211.20 | Next Earning Date: | 02-04-2025 |
| Revenue: | $14,202,000,000 | Revenue Growth: | 8.27% |
| Revenue Growth (this year): | 5.2% | Revenue Growth (next year): | 6.39% |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
StockStory
20 hours ago
2 Healthcare Stocks with Big Upside and 1 to Skip
Investopedia
4 days ago
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
Motley Fool
4 days ago
This Company Just Initiated a Quarterly Dividend: Time to Buy?
Zacks
4 days ago
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
Pharmaceutical Technology
4 days ago
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
GlobeNewswire
4 days ago
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
Zacks
8 days ago
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
Simply Wall St.
9 days ago
Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 11% CAGR delivered to shareholders
Compare REGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.